CSBio CSBio

X
[{"orgOrder":0,"company":"AFT Pharmaceuticals","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Hikma Announces Exclusive Agreement with AFT Pharmaceuticals for Injectable Non-Opioid Pain Medication Combogesic\u00ae IV in the US","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"NEW ZEALAND","productType":"Small molecule","productStatus":"Approved","date":"April 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"AFT Pharmaceuticals"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            Hikma gets rights for the sales, marketing and distribution of Combogesic® IV in the US. Combogesic® IV is a patented intravenous formulation developed as a line extension to Maxigesic tablets, used post-operatively in hospitals when patients cannot take a medicine orally.

            Lead Product(s): Paracetamol,Ibuprofen

            Therapeutic Area: Neurology Product Name: Combogesic IV

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Hikma Pharmaceuticals

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement April 28, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY